IP Library Granted Patent US 8,350,017
Granted Patent B2
US 8,350,017 · App. 13/334,775 · Granted Jan 8, 2013

Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof

Assignees: The Brigham and Women's Hospital, Inc.; Beth Israel Deaconess Medical Center, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,350,017
App. No.
13/334,775
Granted
Jan 8, 2013
Kind
B2
Abstract

The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli . Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli . Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.

Claims (11)

1. An isolated nucleic acid molecule comprising the nucleotide sequences of SEQ ID NO: 37, SEQ ID NO: 38, and SEQ ID NO: 39.

2. The isolated nucleic acid molecule of claim 1 , further comprising the nucleotide sequences of SEQ ID NO: 40, SEQ ID NO: 41 and SEQ ID NO: 42.

3. The isolated nucleic acid molecule of claim 1 , wherein the nucleotide sequences encode a heavy chain variable region of a Staphylococcal poly-N-acetyl glucosamine/dPNAG-binding antibody (PNAG/dPNAG-binding antibody), the heavy chain variable region comprising a CDR1 having an amino acid sequence of SEQ ID NO: 13, a CDR2 having an amino acid sequence of SEQ ID NO:14, and a CDR3 having an amino acid sequence of SEQ ID NO:15.

4. The isolated nucleic acid molecule of claim 1 , wherein the nucleic acid molecule is derived from a hybridoma having Accession No. PTA-5932.

5. The isolated nucleic acid molecule of claim 2 , wherein the nucleic acid molecule is derived from a hybridoma having Accession No. PTA-5932.

6. The isolated nucleic acid molecule of claim 2 , wherein the nucleotide sequences of SEQ ID NOS: 40, 41 and 42 encode a light chain variable region of a Staphylococcal PNAG/dPNAG-binding antibody, the light chain variable region comprising a CDR 1 having an amino acid sequence of SEQ ID NO:16, a CDR2 having an amino acid sequence of SEQ ID NO:17, and a CDR3 having an amino acid sequence of SEQ ID NO:18.

7. An expression vector comprising the isolated nucleic acid molecule of claim 2 , operably linked to a promoter.

8. A host cell transformed or transfected with the expression vector of claim 7 .

9. An expression vector comprising the isolated nucleic acid molecule of claim 1 , operably linked to a promoter.

10. A host cell transformed or transfected with the expression vector of claim 9 .

11. An isolated cell producing an anti- Staphylococcal poly-N-acetyl glucosamine/dPNAG monoclonal antibody (PNAG/dPNAG monoclonal antibody) and having ATCC Accession No. PTA-5932.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2012
From: PIER, GERALD B.; KELLY-QUINTOS, CASIE ANNE
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 029055/0298 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2012
From: CAVACINI, LISA; POSNER, MARSHALL R.
To: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Reel/Frame 029055/0370 →
Continuity (4)
Continuation 12824510 · Jun 28, 2010
Division 11111688 · Apr 21, 2005
Provisional Application 60564105 · Apr 21, 2004
Related Publication 20120196359A1 · Aug 2, 2012